BioLineRx to Present at 15th International Celiac Disease Symposium
News Sep 20, 2013
BioLineRx has announced that its abstract entitled "BL-7010: Non-Absorbable Polymeric Sequestering Agent for Celiac Disease" was accepted for an oral presentation at the 15th International Celiac Disease Symposium, which will take place September 22-25, 2013 in Chicago.
Yotam Nisemblat, Senior Drug Development Manager at BioLineRx, will present BL-7010 for the treatment of celiac as part of a session entitled, "The Non-Responsive Celiac: What's New?"
"We are honored to present BL-7010 at the leading international celiac conference and are excited that the scientific and medical communities share our enthusiasm for this promising and unique product," stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx.
Dr. Savitsky continued, "Despite the unmet medical need and the huge size of the celiac market, there is currently no treatment for the disease apart from a lifelong gluten-free diet, which is extremely difficult to maintain."
"We look forward to commencing a Phase 1/2 study for BL-7010 by the end of this year. The CRO and treatment sites in Europe have already been selected, and we are in the midst of preparing the necessary regulatory submissions for the study," concluded Dr. Savitsky.
New evidence published in the Cochrane Library provides high quality evidence that people who use a combination of nicotine replacement therapies (a patch plus a short acting form, such as gum or lozenge) are more likely to successfully quit smoking than people who use a single form of the medicine.READ MORE